Type 1 fimbrin D-mannose specific adhesin (FimH)

Bacterial adhesin FimH is a 30 kDa protein located at the distal tip of type 1 pili in Gram-negative bacteria, particularly uropathogenic Escherichia coli (UPEC) and adherent-invasive E. coli (AIEC) [2, 15]. It functions as a mannose-specific lectin that mediates the critical first step of infection by binding to mannosylated glycoproteins on host cell surfaces, such as uroplakin Ia in the bladder and CEACAM6 in the intestinal epithelium [3, 18]. FimH is unique for its 'catch-bond' mechanism, where its binding affinity for mannose increases significantly under mechanical shear stress, such as during urine flow, allowing the bacteria to remain anchored to the host [12, 16]. In the context of disease, FimH is a major virulence factor in urinary tract infections (UTIs) and is implicated in the pathogenesis of Crohn's disease by facilitating bacterial colonization and invasion of the gut mucosa [2, 10]. Therapeutic targeting of FimH involves the use of small-molecule mannoside antagonists, such as GSK-3882347 and sibofimloc, which competitively inhibit the lectin domain to prevent bacterial adhesion without exerting the selective pressure typical of traditional antibiotics [1, 5]. This anti-adhesive strategy aims to treat and prevent recurrent infections by 'disarming' the pathogens and facilitating their clearance from the body [6, 8].

Other names

Protein FimHFimH adhesinType 1 fimbrial adhesin FimHD-mannose-specific adhesin

FimH antagonists, primarily mannosides, competitively bind to the mannose-binding lectin domain of the FimH protein [2, 5]. By occupying the binding pocket, these drugs prevent the adhesin from interacting with mannosylated host receptors like uroplakin Ia in the bladder or CEACAM6 in the gastrointestinal tract [3, 18]. This blockade inhibits bacterial attachment, colonization, and subsequent invasion of host tissues, effectively preventing the initiation and progression of infection [6, 11].